TissueGen‘s chief scientist and co-founder, Kevin Nelson, told Drug Delivery Business News the story behind the company he founded in 2000 and its drug delivery technology, the Elute fiber.
DDBN: How did TissueGen get its start?
Nelson: In 1996, while faculty in biomedical engineering at The University of Texas at Arlington, I was working with Dr. Robert Eberhart at the University of Texas Southwestern Medical Center at Dallas. Together, we collaborated with a team to develop a biodegradable vascular stent that had the potential to deliver a live virus to the arterial wall. Simultaneously, I was working with Dr. Nathan Schwade at the Callier Center, Texas Woman’s University to develop a method to deliver non-toxic drugs to the inner ear. The cross-pollination of these two projects, developing fibers for stents and microspheres for otic delivery, inspired me to investigate delivering drugs directly from an extruded fiber.
Get the full story at our sister site, Drug Delivery Business News.
